Clinical Trial: TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection:
Brief Summary: The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
Detailed Summary:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Current Primary Outcome: Overall survival rates of each group [ Time Frame: 3 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Occurrence rate of recurrence of each group [ Time Frame: 3 years ]
Original Secondary Outcome: Same as current
Information By: Eastern Hepatobiliary Surgery Hospital
Dates:
Date Received: October 27, 2015
Date Started: December 2015
Date Completion: December 2017
Last Updated: March 30, 2016
Last Verified: March 2016